{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:43:57Z","timestamp":1784544237106,"version":"3.55.0"},"reference-count":22,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Aim: We aimed to investigate the incidence, treatment patterns, and associated risk factors of type 1 retinopathy of prematurity (ROP) in the only tertiary-level Neonatal Intensive Care Unit (NICU) in Cyprus. Methods: This retrospective study included all infants screened for ROP between January and December 2023. Data were collected from standardized NICU discharge summaries and included gestational age (GA), birth weight (BW), multiple birth, systemic infection, blood transfusion, oxygen therapy, surgical interventions, and ROP outcomes. Infants were categorized into non-ROP, non-type 1 ROP, and type 1 ROP groups. Statistical analysis was performed to identify differences in risk factor distribution. Results: Among 183 infants, 33 (18.0%) developed ROP, with 11 (6.0%) requiring treatment for type 1 ROP. All infants with type 1 ROP were born at \u226428 weeks GA and weighed &lt;1501 g. Type 1 ROP was significantly associated with lower GA, lower BW, systemic infection, surgery, and prolonged oxygen support (p &lt; 0.05). Six infants were treated with laser and three with intravitreal bevacizumab. No recurrence was observed in the anti-VEGF group during 18 months of follow-up. Two infants with aggressive ROP died before treatment. Conclusions: Type 1 ROP in Cyprus occurred exclusively in extremely preterm infants, associated with the cumulative effect of multiple risk factors. Laser remained the primary treatment, while anti-VEGF was used selectively with favorable outcomes. This study emphasizes the importance of tailoring ROP screening and treatment strategies based on individual neonatal risk profiles, supporting a personalized approach to neonatal ophthalmic care.<\/jats:p>","DOI":"10.3390\/jpm15080388","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:29:29Z","timestamp":1755617369000},"page":"388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From Screening to Therapy: A Personalized Approach to ROP in a National NICU Setting"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2028-1060","authenticated-orcid":false,"given":"Stylianos","family":"Christodoulou","sequence":"first","affiliation":[{"name":"Ophthalmology Department Makarios Hospital, Nicosia 2011, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedonas","family":"Herodotou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5764-6721","authenticated-orcid":false,"given":"Annalisa","family":"Quattrocchi","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Potamitis","sequence":"additional","affiliation":[{"name":"Pantheo Eye Centre, Limassol 3076, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi","family":"Choleva","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Makarios Hospital, Nicosia 2011, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: A Meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: A systematic review","volume":"43","author":"Tsiropoulos","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Taher, N.O., Ghaddaf, A.A., Al-Ghamdi, S.A., Homsi, J.J., Al-Harbi, B.J., Alomari, L.K., and Almarzouki, H.S. (2022). Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.884608"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajo.2022.03.020","article-title":"Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated with Intravitreal Bevacizumab or Laser Photocoagulation","volume":"240","author":"Wiecek","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2147\/OPTH.S378520","article-title":"Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity","volume":"16","author":"Zhang","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.survophthal.2021.02.012","article-title":"Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity","volume":"66","author":"Tan","year":"2021","journal-title":"Surv. Ophthalmol."},{"key":"ref_8","unstructured":"(2025, August 13). Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists & British Association of Perinatal Medicine. Available online: https:\/\/curriculum.rcophth.ac.uk\/wp-content\/uploads\/2014\/12\/2008-SCI-021-Guidelines-Retinopathy-of-Prematurity.pdf."},{"key":"ref_9","unstructured":"The Royal College of Ophthalmologists (2025, August 13). Treating Retinopathy of Prematurity in the UK. Clinical Guidelines. March 2022. Available online: https:\/\/www.rcophth.ac.uk."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"de las Rivas Ram\u00edrez, N., Luque Aranda, G., Rius Diaz, F., Perez Frias, F.J., and S\u00e1nchez Tamayo, T. (2022). Risk factors associated with Retinopathy of Prematurity development and progression. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41433-018-0330-x","article-title":"Estimate of incidence of ROP requiring treatment in extreme preterms and impact on service\u20147 year review in tertiary unit","volume":"33","author":"Tavassoli","year":"2019","journal-title":"Eye"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09286586.2019.1606259","article-title":"Perinatal Risk Factors for the Retinopathy of Prematurity in Postnatal Growth and Rop Study","volume":"26","author":"Ying","year":"2019","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaapos.2023.05.008","article-title":"Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab","volume":"27","author":"Yasin","year":"2023","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: A case report","volume":"25","author":"Taylor","year":"2021","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_15","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis","volume":"69","author":"Martorell","year":"2024","journal-title":"Surv. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10792-021-02004-8","article-title":"Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP","volume":"42","author":"Sen","year":"2022","journal-title":"Int. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e39251","DOI":"10.1097\/MD.0000000000039251","article-title":"Six years follow-up of type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab and bevacizumab: Long-Term Outcomes of intravitreal injection in Type 1 ROP","volume":"103","author":"Tung","year":"2024","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.2147\/OPTH.S324614","article-title":"Incidence and Risk Factors for Retinopathy of Prematurity (ROP) in Biggest Neonatal Intensive Care Unit in Itay Elbaroud City, Behera Province, Egypt","volume":"15","author":"Gaber","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Parrozzani, R., Marchione, G., Fantin, A., Frizziero, L., Salvadori, S., Nardo, D., and Midena, G. (2021). Thrombocytopenia as Type 1 ROP Biomarker: A Longitudinal Study. J. Pers. Med., 11.","DOI":"10.3390\/jpm11111120"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: A review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12978-018-0603-7","article-title":"Maternal socioeconomic factors and the risk of premature birth and low birth weight in Cyprus: A case\u2013control study","volume":"15","author":"Kouis","year":"2018","journal-title":"Reprod Health"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:31:16Z","timestamp":1760034676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/8\/388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jpm15080388"],"URL":"https:\/\/doi.org\/10.3390\/jpm15080388","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}